Skip to main content

Spinal Cord Injury

Spinal cord injury (SCI) is the archetypal reconstructive neuro-urology population. Nearly 100% of patients with SCI above the conus develop NLUTD, and without structured urologic surveillance CKD / ESRD was historically the leading cause of mortality. The level of injury, completeness, and interval since injury all drive the NLUTD phenotype. Sean Elliott and others have emphasized that the urologist's role in SCI is longitudinal — from the acute spinal-shock catheter drainage through decades of risk-stratified surveillance and, when necessary, reconstructive surgery.[1][2][3]

This article focuses on SCI-specific points. For general NLUTD principles see Neurogenic Lower Urinary Tract Dysfunction; for a life-threatening SCI-specific emergency see Autonomic Dysreflexia.

Epidemiology​

  • US prevalence ~250,000–300,000; incidence ~17,000/year.
  • Leading etiologies: motor-vehicle trauma, falls, violence, sports, non-traumatic (transverse myelitis, tumor, ischemia).
  • Average age at injury is rising (currently ~43 years) — aging of the SCI population brings coexisting BPH, prostate cancer, and obesity into reconstructive planning.
  • Life expectancy in SCI has approached general-population levels for C5 and below; upper-tract complications and pressure injury remain leading preventable causes of death.

Pathophysiology by Level​

Injury levelPhase after injuryDominant urodynamic phenotype
Any levelAcute / spinal-shock (days–~6 weeks, range up to months)Detrusor areflexia + intact distal sphincter tone; urinary retention
Above T6 (high cervical / upper thoracic)After spinal shockDetrusor overactivity + DSD + risk of autonomic dysreflexia
T6–T12 / suprasacralAfter spinal shockDO + DSD; lower AD risk
Conus (T12–L1 region)Stable from onsetVariable — can resemble suprasacral DSD or sacral areflexia
Cauda equina / sacral / infrasacralStable from onsetDetrusor areflexia + denervated EUS; retention, overflow, stress incontinence

Initial Evaluation and Surveillance Cadence​

Per AUA/SUFU 2021 risk-stratified framework.[1][2] Most SCI patients are high-risk or unknown-risk and warrant baseline multichannel video-urodynamics once spinal shock resolves (typically 3–6 months post-injury, earlier if upper-tract changes appear).

Baseline workup (3–6 months post-injury):

  • History + exam (including AD triggers, skin, bowel program)
  • Urinalysis, serum Cr / eGFR
  • Renal ultrasound
  • Video-urodynamics — documents DO, DSD, DLPP, compliance, VUR
  • PVR + bladder diary

Longitudinal surveillance (high-risk):

  • Clinic visit + UA every 6–12 months
  • Renal ultrasound annually (or every 1–2 years if stable)
  • eGFR annually
  • Urodynamics when clinical change (new symptoms, hydronephrosis, declining function, new AD pattern)
  • Cystoscopy annually in patients with long-term indwelling catheters (>5–10 years) for SCC surveillance

Management​

Emptying strategies — order of preference[2][3][4]​

  1. Clean intermittent catheterization (CIC) — the gold standard. 4–6×/day; hydrophilic or closed-system kits reduce UTI and urethral trauma.
  2. Indwelling SPC — when dexterity / caregiver support / body habitus preclude CIC. Preferred over indwelling urethral catheter in men to protect the urethra.
  3. Indwelling urethral catheter — last-line; high urethral-erosion risk in men, bladder-neck and sphincter damage in women.
  4. Reflex voiding with external condom drainage (men) — historically common; requires confirmed safe pressures and no DSD. Reflex voiding women: not practical — no condom-drainage equivalent.
  5. Credé / Valsalva — avoid in suprasacral lesions (raises storage pressure); acceptable in sacral areflexic bladder with low outlet resistance.

Pharmacologic​

  • Antimuscarinics first-line for DO; combination with β3 agonist when monotherapy inadequate. See Neurogenic Lower Urinary Tract Dysfunction for agent table.
  • Intradetrusor onabotulinumtoxinA 200 U — highly effective for neurogenic DO in SCI; repeat ~6–9 months; patient must be CIC-capable pre-treatment.[4]
  • α-blockers for mild DSD and to reduce outlet resistance in CIC-dependent patients.

Surgical​

  • Augmentation cystoplasty — hostile bladder refractory to medical therapy + botulinum. Typically ileum; ileocecal in selected cases.
  • Mitrofanoff / Monti catheterizable channel — wheelchair-dependent patients, obese patients with urethral inaccessibility, patients with prior urethral reconstruction.
  • Bladder-neck closure + continent catheterizable channel — for persistent outlet leakage with CIC-through-channel working.
  • Ileal conduit / continent diversion — salvage when reconstruction has failed or is not feasible.
  • Sacral neuromodulation — not routinely recommended in complete SCI; outcomes variable.[2]
  • External sphincterotomy — largely historical; replaced by CIC + medical therapy in most men.

SCI-specific perioperative caveats​

  • Autonomic dysreflexia — every cystoscopy, urodynamics, and OR case in T6-and-above SCI requires AD prevention: topical lidocaine, BP monitoring, short-acting antihypertensives (nifedipine, nitrate) available. See Autonomic Dysreflexia.
  • Positioning and pressure injury — lithotomy / prone positioning with insensate skin; meticulous padding, frequent repositioning, and postop skin checks.
  • Spasticity — baclofen pumps and botulinum-for-limb-spasticity regimens may interact with bladder care timing.
  • Heterotopic ossification — at hips; affects access and positioning.

Specific Scenarios​

Indwelling catheter exit — transitioning to CIC​

Many patients arrive with long-term indwelling catheters "because it's easier." Transition to CIC or SPC reduces UTI, stone, and SCC risk — but requires dexterity (C7 or better typically), caregiver support, and motivation. Dedicated SCI nurse education drives success.

Bladder cancer surveillance​

  • Long-term indwelling catheter (>5–10 years) is associated with increased bladder SCC risk.
  • Annual cystoscopy + urine cytology in this cohort is reasonable.
  • Any gross hematuria, persistent irritative symptoms, or pelvic pain warrants cystoscopy regardless of surveillance schedule.

Fertility and sexual health​

  • Erectile dysfunction — PDE5i first-line; intracavernosal injection or penile prosthesis in refractory cases.
  • Ejaculatory dysfunction — penile vibratory stimulation (PVS) first-line; electroejaculation (EEJ) if PVS fails; retrieved sperm used with IUI / IVF / ICSI.
  • Female SCI — fertility preserved; pregnancy-specific bladder management plan required; delivery planning with OB/GYN.

Aging SCI population​

  • BPH — increasingly common; treating in CIC patients requires balancing outlet resistance (needed for dry intervals between CIC) vs ease of catheter passage.
  • Prostate cancer — screening with PSA in SCI follows general guidelines; transrectal biopsy requires AD prophylaxis.
  • Falls, cognitive decline, caregiver changes — trigger reassessment of feasible bladder management.

Clinical Correlations for the Reconstructive Urologist​

  • The first 3–6 months matter. Establish safe drainage (SPC or CIC) during spinal shock; schedule baseline video-urodynamics as soon as reflex patterns stabilize. Delay in this window is where upper-tract deterioration starts.
  • Hostile bladder in SCI is reversible if caught early. Escalate aggressively — antimuscarinic + β3 → botulinum → augmentation cystoplasty. Do not wait for eGFR decline.
  • Care is multidisciplinary. SCI medicine physiatrist, urologist, neuro-urology nurse / educator, physical therapy, and social work are the standard team.
  • Transition from pediatric SCI / spina bifida — aging-out patients need deliberate handoff to adult reconstructive urology; otherwise they fall out of surveillance and present years later with advanced disease.

References​

1. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult NLUTD: Diagnosis and Evaluation." J Urol. 2021;206(5):1097–1105. doi:10.1097/JU.0000000000002235

2. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult NLUTD: Treatment and Follow-Up." J Urol. 2021;206(5):1106–1113. doi:10.1097/JU.0000000000002239

3. Milligan J, Goetz LL, Kennelly MJ. "A Primary Care Provider's Guide to Management of NLUTD and UTI After Spinal Cord Injury." Top Spinal Cord Inj Rehabil. 2020;26(2):108–115. doi:10.46292/sci2602-108

4. Romo PGB, Smith CP, Cox A, et al. "Non-Surgical Urologic Management of Neurogenic Bladder After Spinal Cord Injury." World J Urol. 2018;36(10):1555–1568. doi:10.1007/s00345-018-2419-z